Tag: Non stimulant adhd

According to the DEA, stimulant medications for ADHD are Schedule II controlled substances due to their high potential for abuse. For those concerned about dependency, finding out which ADHD medication is the least addictive is a critical step in exploring safer, effective treatment options.

According to a 2023 review, a multimodal approach is crucial for adult ADHD care, and many people seek alternatives to the common stimulant Adderall due to side effects or ineffectiveness. Finding **what prescription is better than Adderall** depends entirely on an individual’s unique response to different medications, not a one-size-fits-all solution.

According to a 2013 review in *Psychopharmacology*, atomoxetine was found to lack significant abuse potential, unlike traditional stimulants, highlighting what is the least addictive ADHD med. This is a crucial consideration for patients seeking effective treatment with minimal risk of dependency.

An estimated 6.1 million children in the U.S. have been diagnosed with ADHD [1.3.8]. While the brand name medication Strattera has been discontinued, the answer to 'What is the new name for Strattera?' is its generic name: **atomoxetine** [1.4.4, 1.4.7].

As of late 2023, the brand-name ADHD medication Strattera was officially discontinued by its manufacturer, Eli Lilly, primarily due to declining market share following the introduction of less-expensive generic versions. This decision was a business move, not a recall based on safety concerns regarding the original drug.

As of late 2024, the U.S. Food and Drug Administration (FDA) approved Onyda XR, the first liquid non-stimulant ADHD medication for children and adolescents aged six years and older. This milestone is part of an expanding range of options for what is the new drug for ADHD, offering alternatives to traditional stimulant treatments and diverse formulations to fit individual needs.